雌激素干预影响腹腔脂肪积聚的实验研究

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (6): 669-672.

雌激素干预影响腹腔脂肪积聚的实验研究

朱晓晖, 王军, 印彤

南通医学院附属医院内分泌科,南通 226001,江苏

收稿日期:2003-05-19 修回日期:2003-07-07 出版日期:2003-12-26 发布日期:2020-11-19
通讯作者: 王军,男,医学博士,副主任医师,研究方向:神经内分泌系统中性激素作用机制。Tel:0513-5598825 　E-mail:ntjunhui@pub.nt.jsinfo.net
作者简介:朱晓晖,女,副教授,副主任医师,研究方向:激素作用机制和临床治疗。

Effects of estrogen interference on abdominal adipose accumulation in mice

ZHU Xiao-Hui, WANG Jun, YIN Tong

Department of Endocrinology,Affiliated Hospital to Nantong Medical College,Nantong 226001,Jiangsu,China

Received:2003-05-19 Revised:2003-07-07 Online:2003-12-26 Published:2020-11-19

摘要/Abstract

摘要： 目的研究雌激素干预对雌性C57BL/6J 小鼠腹腔脂肪代谢的影响。方法采用卵巢切除法造成雌激素缺乏模型,以及在动情周期正常和围绝经期的小鼠中,给以雌激素干预,观察腹腔脂肪重量的变化。3 mon 龄小鼠随机分为正常组,卵巢切除组,给雌激素15 d 组和给雌激素60 d 组,每组10 只。小鼠摘除卵巢后饲养至7 mon 龄处死。5 和10 mon 龄小鼠分为正常组,动情周期正常+雌激素60 d组,围绝经期组和围绝经期+雌激素60 d 组,每组10只,分别饲养至7 和12 mon 龄处死,检测腹腔脂肪重量。各组小鼠于处死前15 和60 d 分别皮下埋植控释雌激素(17β-雌二醇)药丸(0 .18 mg/丸)。结果卵巢切除组腹腔脂肪重量明显增加(P<0 .05);给雌激素15 d 组腹腔脂肪重量减轻(P<0 .05);给雌激素60 d 组腹腔脂肪重量有明显减轻,与正常组比较无显著性差别(P>0 .05)。动情周期正常+雌激素组和围绝经期+雌激素组的小鼠,其腹腔脂肪重量的变化无差别。结论卵巢切除明显影响小鼠的脂肪代谢导致腹腔脂肪积聚,而雌激素干预,特别是长期应用,可以明显减少小鼠的腹腔脂肪积聚。外源性雌激素干预在动情周期正常和围绝经期对小鼠腹腔脂肪没有明显的影响。

关键词: 药效学, 小鼠, 卵巢切除, 雌激素干预, 腹腔脂肪, 围绝经期, 动情周期

Abstract: AIM: To investigate the effects of estrogen interference on abdominal adipose accumulation in C7BL/6J mice.METHODS: Estrogen was administrated to the ovariectomized mice(estrogen-deprived model)and the changes of abdominal adipose weight of the mice in the normal estrous cycle andPro-menopausal were observed.Mice of 3 months old were randomly divided into control,ovariectomized(OVX),OVX +estrogen 15-days(E d 15)and OVX + estrogen 60-days(E d 60)groups.Each grouPhad 10 mice.Mice were raised and sacrificed until 7 months old after ovariectomized.5 months and 10 months old mice were divided into control,estrous cycle normal +estrogen 60 days,pro-menopausal andPro-menopausal +60 days groups.17β-estradiol timereleasePellets(0.18 mg/pellet)were given ic in 15 days and 60 days before mice were sacrificed.RESULTS: The abdominal adipose weight in OVX grouPincreased significantly(P<0.05).The abdominal adipose weight in E d 15 grouPshowed slightly decreased,but was still significant difference(P<0.05).The abdominal adipose weight in E d 60 grouPdecreased significantly and showed no difference compared to control grouP(P>0.05).There was no difference in the abdominal adipose weight between control and estrous cycle normal + estrogen 60-days groups,and betweenPro-menopausal andPro-menopausal + estrogen 60-days groups.CONCLUSION: Ovariectomy significantly influences the metabolism of abdominal adipose that causes adipose accumulation.Estrogen interference,especiallylong-term administration,can attenuate the abdominal adipose accumulation.Exogenous estrogen interference has no effect on abdominal adipose accumulation on cycle normal andPro-menopausal mice.

Key words: pharmacology, mice, ovariectomy, estrogen interference, abdominal adipose :estrous cycle, pro-menopause

中图分类号:

R965

朱晓晖, 王军, 印彤. 雌激素干预影响腹腔脂肪积聚的实验研究[J]. 中国临床药理学与治疗学, 2003, 8(6): 669-672.

ZHU Xiao-Hui, WANG Jun, YIN Tong. Effects of estrogen interference on abdominal adipose accumulation in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 669-672.

参考文献

1 Walsh BW,Schiff I,Rosner B,et al.Effects ofPostmenopausal estrogen replacement on the concentrations and metabolism ofPlasmalipoproteins[J].N Engl J Med,1991;325:1196-204
2 Ettinger B,Friedman D,Bush T,et al.Reduced mortality associated withlong-termPost-menopausal estrogen therapy[J].Obstet Gynecol,1996;87:6-12
3 Naaz A,Zakroczymski M,HeineP,et al.Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha(ERalpha):aPotential role for estrogen receptor beta(ERbeta)[J].Horm Metab Res,2002;34:758-63
4 Carey DG,Jenkins AB,CampelllV,et al.Abdominal fat and insulin resistance in normal and overweight women:direct measures reveal a strong relationshiPin subjects at bothlow and high risk of NIDDM[J].Diabetes,1996;45:633-8
5 Witteman JC,Grobbee DE,Kok FJ,et al.Increased risk of atherosclerosis in women after the menopause[J].Br Med J 1989;298:642-4
6 EdwinlB,John AG.Disorders oflipid metabolism[A].In:Robert HW,ed.Textbook of Endocrinology[M].Philadelphia:PA.W.B.Saunders,1992:1367
7 Haarbo J,Leth-EspensenP,Stender S,et al.Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits[J].J Clin Invest,1991;87:1274-9
8 Haarbo J,Marslew U,Gotfredsen A,et al.Postmenopausal hormone replacement therapyPrevents central distribution of body fat after the menopause[J].Metabolism,1991;40:1323-6
9 Belanger C,Luu-The V,DupontP,et al.Adipose tissue intracrinology:potential importance oflocal androgen estrogen metabolism in the regulation of adiposity[J].Horm Metab Res,2002;34:737-45
10 Mattiasson I,Rendell M,Tomquist C,et al.Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose andlipid metabolism in earlyPostmenopausal women[J].Horm Metab Res,2002;34:583-8
11 Hirvonen E,Malkonen M,Manninen V.Effects of differentProgestogens onlipoproteins duringPostmenopausal replacement therapy[J].N Engl JMed,1981;304:560-6

[1]	杜彩凤, 毛宇楠, 高嘉, 王娟, 李小叶, 田俊生, 刘宏奇. 基于1H-NMR代谢组学的绝经期综合征血清代谢标志物研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 961-968.
[2]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[3]	王珍, 全海燕, 洪陈亮, 袁李佳龙, 秦旭平. 游泳运动通过促进自噬改善糖尿病小鼠肾功能的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 632-638.
[4]	何欢, 薛震宇, 毛豪丽, 张磊. 长时间七氟烷暴露对老年小鼠前额叶皮质代谢组学的影响[J]. 中国临床药理学与治疗学, 2022, 27(12): 1375-1380.
[5]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[6]	徐俪颖王淑华张高松黄继汉黄小民. 和胃止泻胶囊治疗腹泻患者的临床疗效和模型化评价[J]. 中国临床药理学与治疗学, 2022, 27(1): 47-55.
[7]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[8]	刘云帆, 杜月梅, 刘晓艺, 高丽萍. 枸杞多糖对顺铂诱导小鼠睾丸支持细胞凋亡的影响[J]. 中国临床药理学与治疗学, 2021, 26(6): 624-630.
[9]	章思亮, 胡琳璘, 邵华, 陈西敬. 性别差异对精神药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(3): 324-331.
[10]	焦正, 李新刚, 尚德为, 董婧, 左笑丛, 陈冰, 刘剑敏, 潘雁, 周田彦, 张菁, 刘东阳, 李禄金, 方翼, 马广立, 丁俊杰, 赵维, 陈锐, 相小强, 王玉珠, 高建军, 谢海棠, 胡蓓, 郑青山. 模型引导的精准用药：中国专家共识（2021版）[J]. 中国临床药理学与治疗学, 2021, 26(11): 1215-1228.
[11]	李文超, 白向荣, 李晓玲, 姜德春. 替加环素在治疗感染性疾病中的群体药代动力学/药效学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(11): 1265-1272.
[12]	向荣凤, 孙凤军, 熊丽蓉, 喻明洁, 戴青, 陈勇川. 左旋泮托拉唑钠肠溶片在健康人体内的药代动力学和药效学研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 903-909.
[13]	孔祥, 华强, 姚新明, 孟祥健, 钟民, 郭莉群. 芝麻酚调控巨噬细胞极化改善肥胖小鼠脂肪组织炎症及胰岛素抵抗[J]. 中国临床药理学与治疗学, 2020, 25(7): 728-733.
[14]	彭静, 刘俊, 许慧芳, 李越然, 江佳, 汪盛, 周德喜, 朱艳虹, 杨魁, 栾家杰. 细胞色素P4502C19基因多态性及代谢型与ADP诱导的血小板聚集抑制率及氯吡格雷抵抗的关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 746-751.
[15]	蔡妙国，邵卫，俞慧君，洪叶，施莉莉. SNI小鼠中调控ROS对疼痛和脊髓Pink1蛋白的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1263-1268.